Skip to content
10-Q

Quarterly Report

Calidi Biotherapeutics, Inc. CLDI CLDWW

0001493152-26-023140

← back to feed
Filed
May 14, 2026 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 8, 2026 19.31M sh
Shares Diluted Q1 2026 · Mar 31, 2026 10.31M sh
Shares Diluted restated Q1 2026 · Mar 31, 2025 2.26M sh
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$4.12M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$7.13M
Long Term Debt Q1 2026 · Mar 31, 2026 $600K
Long Term Debt Q1 2026 · Dec 31, 2025 $600K
Short Term Debt Q1 2026 · Mar 31, 2026 $23K
Short Term Debt Q1 2026 · Dec 31, 2025 $90K
Stockholders Equity Q1 2026 · Mar 31, 2026 $4.94M
Stockholders Equity Q1 2026 · Dec 31, 2025 $3.76M
Current Liabilities Q1 2026 · Mar 31, 2026 $3.84M
Current Liabilities Q1 2026 · Dec 31, 2025 $3.94M
Total Liabilities Q1 2026 · Mar 31, 2026 $4.66M
Total Liabilities Q1 2026 · Dec 31, 2025 $5.1M
Current Assets Q1 2026 · Mar 31, 2026 $7.35M
Current Assets Q1 2026 · Dec 31, 2025 $6.26M
Total Assets Q1 2026 · Mar 31, 2026 $9.59M
Total Assets Q1 2026 · Dec 31, 2025 $8.86M
Eps Diluted Q1 2026 · Mar 31, 2026 −$0.43
Eps Diluted restated Q1 2026 · Mar 31, 2025 −$2.21
Eps Basic Q1 2026 · Mar 31, 2026 −$0.43
Eps Basic restated Q1 2026 · Mar 31, 2025 −$2.21
Sga Expense Q1 2026 · Mar 31, 2026 $1.6M
Sga Expense Q1 2026 · Mar 31, 2025 $2.64M
Rd Expense Q1 2026 · Mar 31, 2026 $2.59M
Rd Expense Q1 2026 · Mar 31, 2025 $2.43M
Net Income Q1 2026 · Mar 31, 2026 −$4.11M
Net Income restated Q1 2026 · Mar 31, 2025 −$4.99M
Operating Income Q1 2026 · Mar 31, 2026 −$4.19M
Operating Income Q1 2026 · Mar 31, 2025 −$5.06M